

SUPERNUS PHARMACEUTICALS INC  
Form SC 13D/A  
December 08, 2014

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

SCHEDULE 13D/A

INFORMATION TO BE INCLUDED IN  
STATEMENTS FILED PURSUANT  
TO RULE 13d-1(a) AND AMENDMENTS  
THERE TO FILED PURSUANT TO  
RULE 13d-2(a)

Under the Securities Exchange Act of 1934  
(Amendment No. 2)

Supernus Pharmaceuticals, Inc.  
(Name of Issuer)

Common Stock, par value \$0.001 per share  
(Title of Class of Securities)

868459108  
(CUSIP Number)

Orchard Hill Capital Management LP

152 W. 57<sup>th</sup> Street, 41<sup>st</sup> Floor  
New York, NY 10019  
Attention: Mitchell Vogel  
(212) 521-1150  
(Name, Address and Telephone Number of Person  
Authorized to Receive Notices and  
Communications)

December 4, 2014  
(Date of Event which Requires  
Filing of this Schedule)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. [ ]

**NOTE:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

(Continued on following pages)

(Page 1 of 4 Pages)

-----  
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

|   |  |
|---|--|
|   | NAME OF REPORTING PERSON   |
| <b>1</b>  | Orchard Hill Capital Management LP   |
|   | CHECK THE APPROPRIATE BOX IF A MEMBER OF (b) A GROUP   |
| <b>2</b>  |  |
| <b>3</b>  | SEC USE ONLY SOURCE OF FUNDS   |
| <b>4</b>  | AF CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) CITIZENSHIP OR PLACE OF ORGANIZATION |
| <b>5</b>  |  |
| <b>6</b>  | Delaware<br>SOLE VOTING POWER<br><br>224,419 Shares  |
|   | <b>7</b> 2,020,663 Shares issuable upon conversion of Convertible Notes  |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | <b>8</b> SHARED VOTING POWER   |
|   | <b>9</b> 0 SOLE DISPOSITIVE  |

POWER

224,419 Shares

2,020,663  
Shares issuable  
upon  
conversion of  
Convertible  
Notes

SHARED  
DISPOSITIVE  
POWER

10

0

AGGREGATE  
AMOUNT  
BENEFICIALLY  
OWNED BY EACH  
PERSON

11

224,419 Shares

2,020,663 Shares  
issuable upon conversion  
of Convertible Notes

CHECK IF THE  
AGGREGATE  
AMOUNT IN  
ROW (11)      ..  
EXCLUDES  
CERTAIN  
SHARES

12

PERCENT OF CLASS  
REPRESENTED BY  
AMOUNT IN ROW (11)  
(see Item 5)

13

4.99% (See Item 5)  
TYPE OF REPORTING  
PERSON

14

IA

CUSIP No. 868459108 SCHEDULE 13D/A Page 3 of 4 Pages

This Amendment No. 2 ("Amendment No. 2") amends and supplements the statement on Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on July 7, 2014 (the "Original Schedule 13D") and Amendment No. 1 filed with the SEC on September 9, 2014 ("Amendment No. 1" and together with the Original Schedule 13D and this Amendment No. 2, the "Schedule 13D") with respect to the shares ("Shares") of common stock, par value \$0.001 per share, of Supernus Pharmaceuticals, Inc., a Delaware corporation (the "Issuer"). Capitalized terms used herein and not otherwise defined in this Amendment No. 2 have the meanings set forth in the Schedule 13D. This Amendment No. 2 amends Items 3, 5 and 7 as set forth below. This is the final amendment to the Schedule 13D and is an exit filing for the Reporting Person.

**Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.**

Item 3 of the Schedule 13D is hereby amended and restated as follows:

The 2,245,082 Shares (including the Convertible Notes) reported herein by the Reporting Person were acquired at an aggregate purchase price of approximately \$15,550,856. Such Shares (and the Convertible Notes) were acquired with the working capital of the Fund and margin account borrowings made in the ordinary course of business. In such instances, the positions held in the margin accounts are pledged as collateral security for the repayment of debit balances in the account, which may exist from time to time. Since other securities are held in the margin accounts, it is not possible to determine the amounts, if any, of margin used to purchase the Shares or Convertible Notes reported herein.

**Item 5. INTEREST IN SECURITIES OF THE COMPANY.**

Items 5(a), (b), (c) and (e) of the Schedule 13D are hereby amended and restated in their entirety as follows:

See rows (11) and (13) of the cover page to this Schedule 13D for the aggregate number of Shares and the percentage of the Shares beneficially owned by the Reporting Person. The percentage reported in this Amendment (a) No. 2 is calculated based upon the 42,930,326 Shares reported to be outstanding as of October 31, 2014, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2014, and assumes conversion of the Convertible Notes.

See rows (7) through (10) of the cover page to this Amendment No. 2 for the number of Shares as to which each (b) Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

(c) Information concerning transactions in the Shares effected by the Reporting Person during the past sixty days is set forth in Exhibit A hereto and is incorporated herein by reference.

(e) December 8, 2014.

**Item 7.**

**MATERIAL TO BE FILED AS  
EXHIBITS.**

Exhibit A: Transactions in the Shares During the Last 60 Days.

**SIGNATURES**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: December 8, 2014

**ORCHARD HILL  
CAPITAL MANAGEMENT  
LP**

By: /s/ Mitchell Vogel  
Name: Mitchell Vogel  
Title: Chief Financial Officer